Results 11 to 20 of about 790,730 (234)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors [PDF]

EMBO Molecular Medicine, 2020
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen   +15 more
doaj   +2 more sources

Siah2 control of T-regulatory cells limits anti-tumor immunity. [PDF]

, 2020
Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-based cancer therapies. Here, we report that growth of BRAF-mutant melanoma cells is inhibited, up to complete rejection, in Siah2-/- mice.
Aifantis, Ioannis, Bosenberg, Marcus, Bradley, Linda M, Brown, Kevin, Dolgalev, Igor, Feng, Yongmei, Hockemeyer, Kathryn, Li, Yan, Marine, Jean-Christophe, Otero, Dennis C, Poźniak, Joanna, Rambow, Florian, Ronai, Ze'ev A, Scortegagna, Marzia, Tinoco, Roberto, Zhang, Tongwu   +15 more
core   +2 more sources

USE OF NEAR INFRARED TECHNOLOGY TO PREDICT FATTY ACID GROUPS IN COMMERCIAL GROUND MEAT PRODUCTS [PDF]

Poljoprivreda, 2015
Near infrared transmittance (NIT, 850 to 1048 nm) spectroscopy was used to predict groups of fatty acids (FA), namely saturated FA (SFA), monounsaturated FA (MUFA) and polyunsaturated FA (PUFA), in commercial ground meat samples aiming to develope a fast
Sofia Ton, Massimo De Marchi, Davide Manfrin, Michele Meneghesso, Martino Cassandro , Mauro Penasa   +5 more
doaj   +1 more source

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy

Frontiers in Immunology, 2021
Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the treatment of several cancers.
Yuanyuan Wang, Yuanyuan Wang, Tingxuan Gu, Tingxuan Gu, Xueli Tian, Xueli Tian, Wenwen Li, Ran Zhao, Ran Zhao, Wenqian Yang, Wenqian Yang, Quanli Gao, Tiepeng Li, Jung-Hyun Shim, Chengjuan Zhang, Kangdong Liu, Kangdong Liu, Mee-Hyun Lee, Mee-Hyun Lee, Mee-Hyun Lee   +19 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

A dangerous mixture

Italian Journal of Medicine, 2014
A 59-year old woman was admitted for fatigue and arm paresthesias with Trousseau sign. Her medical history included thyroidectomy and hypercholesterolemia recently treated with simvastatin.
Anna Piva, Alessio Filippi, Natalino Simioni   +2 more
doaj   +1 more source

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Molecules, 2021
Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer ...
Hongbo Zhang, Yu Xia, Chunqiu Yu, Huijie Du, Jinchang Liu, Hui Li, Shihui Huang, Qihua Zhu, Yungen Xu, Yi Zou   +9 more
doaj   +1 more source

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma

Zhongliu Fangzhi Yanjiu, 2020
Malignant melanoma is the most serious type of skin cancer with a high recurrence rate and death rate. Surgery still is the cornerstone of treatment for patients with stage Ⅱ and Ⅲ melanoma.
ZOU Hanhui, Li Tao
doaj   +1 more source

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Journal of Hematology & Oncology, 2021
CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL).
Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han   +10 more
doaj   +1 more source

Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report

Frontiers in Oncology, 2023
BackgroundGastric cancer (GC) is the third most common cause of cancer-related death in the world. Several clinical trials have proven that the use of PD-1/PD-L1 inhibitors can improve the survival of late-stage GC patients and is suggested in NCCN and ...
Qijun Wang, Qijun Wang, Qijun Wang, Qijun Wang, Qijun Wang, Zhewei Shen, Zhewei Shen, Zhewei Shen, Zhewei Shen, Zhewei Shen, Mengxi Ge, Jie Xu, Xin Zhang, Xin Zhang, Xin Zhang, Xin Zhang, Xin Zhang, Wei Zhu, Wei Zhu, Wei Zhu, Wei Zhu, Wei Zhu, Jie Liu, Wei Hua, Wei Hua, Wei Hua, Wei Hua, Wei Hua, Ying Mao, Ying Mao, Ying Mao, Ying Mao, Ying Mao   +32 more
doaj   +1 more source